TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03870672

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Contralaterally Controlled Functional Electrical Stimulation
Description: Contralaterally Controlled Functional Electrical Stimulation (CCFES) uses electrical stimulation to open the weak hand. Sticky patches called electrodes are placed on the participant's affected arm to stimulate the hand muscles, and a special glove is worn on the participant's strong hand and controls the stimulator. When the participant opens the gloved hand, stimulation opens the weak hand; when they close the gloved hand, stimulation turns off and the weak hand relaxes. During the clinic visits, participants will use CCFES to assist hand opening during functional training. During participant home sessions, they will use CCFES to perform hand opening exercise.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Contralaterally Controlled Functional Electrical Stimulation
Description: Contralaterally Controlled Functional Electrical Stimulation (CCFES) uses electrical stimulation to open the weak hand. Sticky patches called electrodes are placed on the participant's affected arm to stimulate the hand muscles, and a special glove is worn on the participant's strong hand and controls the stimulator. When the participant opens the gloved hand, stimulation opens the weak hand; when they close the gloved hand, stimulation turns off and the weak hand relaxes. During the clinic visits, participants will use CCFES to assist hand opening during functional training. During participant home sessions, they will use CCFES to perform hand opening exercise.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Contralaterally Controlled Functional Electrical Stimulation
Description: Contralaterally Controlled Functional Electrical Stimulation (CCFES) uses electrical stimulation to open the weak hand. Sticky patches called electrodes are placed on the participant's affected arm to stimulate the hand muscles, and a special glove is worn on the participant's strong hand and controls the stimulator. When the participant opens the gloved hand, stimulation opens the weak hand; when they close the gloved hand, stimulation turns off and the weak hand relaxes. During the clinic visits, participants will use CCFES to assist hand opening during functional training. During participant home sessions, they will use CCFES to perform hand opening exercise.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: New rTMS approach
Description: Participants in this arm will receive rTMS-based facilitation of the contralesional dorsal premotor cortex (cPMd) located in the non-stroke hemisphere before start of each session. High-frequency rTMS (5-Hz) will be delivered using 42 10-sec trains of 50 pulses each (total 2100 pulses) for a period of 24 minutes. Immediately after the completion of rTMS, participants will undergo upper limb training + CCFES for a total of one hour. Participants will receive these interventions 2 days a week for 12 weeks.
Study: NCT01427972

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2623091
Description: Administered orally
Study: NCT03870672

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional rTMS approach
Description: Facilitation of M1 will be achieved using 5Hz rTMS. High-frequency rTMS (5-Hz) will be delivered using 42 10-sec trains of 50 pulses each (total 2100 pulses) for a period of 24 minutes. Immediately after the completion of rTMS, participants will undergo upper limb training + CCFES for a total of one hour. Participants will receive these interventions 2 days a week for 12 weeks.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham rTMS approach
Description: In the sham rTMS group, ipsilesional motor hotspot will be targeted in half the patients and cHMC location will be targeted in the other half (based on random assignment). Immediately after the completion of rTMS, participants will undergo upper limb training + CCFES for a total of one hour. Participants will receive these interventions 2 days a week for 12 weeks.
Study: NCT00005092

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: IV over 2 hours on days 2 and 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psoralen
Description: Psoralen treated T-cell allogeneic transplant on day 9
Study: NCT04060004

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electrotherapy + therapeutic exercise
Description: Standard care of neck pain.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Electrotherapy + therapeutic exercise
Description: Standard care of neck pain.
Study: NCT00995098

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: early enteral nutrition
Description: Enteral nutrition will be administered within 24 hours of admission through naso-jejunal tube and continue for 7 days after admission. Naso-jejunal tube will be set up by endoscopy. X-ray will be used to place the distal end of the feeding tube and EN would not start until the distal end of the feeding tube has been placed at the remote end of Treitz ligament. Standard enteral nutrition liquid regimen (Nutrison Fibre) will be used. Patients are targeted to receive calories for 25 kcal/kg/day and nitrogen for 0.2g/kg/day.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Parenteral nutrition
Description: PN administration will start within 12 hours of admission and continue for 7 days after admission. Patients will receive calories for 25 kcal/kg and nitrogen for 0.2g/kg. Twenty percent of the calories will be provided by fat emulsion (LCT/MCT) and the remaining will be provided by dextrose. Nitrogen will be provided by balanced amino acids injection (Novamin). All PN components will be compounded into 3-liters bags under sterile conditions. Nutrition regimen will be administered through subclavian central venous catheter.
Study: NCT04099498

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Program: Healthy Eating Promotion with Self-regulation
Description: Online-Intervention group

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Online Program: Healthy Eating Promotion with Self-regulation
Description: Enhanced-online-Intervention Group
Study: NCT03196596

Intervention type: OTHER
Intervention: Computer simulation
Description: In these patients, a computer simulation model will be obtained based on pre procedural CT
Study: NCT04717271

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Movement Guidance Group
Description: Participants of the MVG will received kinesthetic stimuli by manual assistance of the physiotherapist, which has the intention of guiding and improving the quality of movement during XBOX Kinect training for balance and gait.~Each session consisted of 10 minutes of warm-up and 40 minutes of XBOX Kinect training, using 4 different exergames.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No Movement Guidance Group
Description: Participants of the NO-MVG will not received kinesthetic stimuli by manual assistance of the physiotherapist during XBOX Kinect training for balance and gait.~They will perform the exercises without any manual correction. Although, the physiotherapist will be present during all session to ensure their safety.~Each session consisted of 10 minutes of warm-up and 40 minutes of XBOX Kinect training, using 4 different exergames.
Study: NCT01222819

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: 5 mcg/kg (rounded to 300 mcg or 480 mcg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: filgrastim
Description: 5 mcg/kg (rounded to 300 mcg or 480 mcg)
Study: NCT04342676

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: k ras
Description: K ras
Study: NCT01427972

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2623091
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2623091
Description: Administered orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eplerenone
Description: Administered orally
Study: NCT03513367

Intervention type: OTHER
Intervention: Duchenne Muscular Dystrophy of the PedsQL ™ 3.0 scale
Description: Scaling in multidisciplinary consultations in the form of a self-administered questionnaire with the help of a third party (psychologist). The child and his / her parent complete the questionnaire independently. The result of the questionnaire will then be scored.~To validate the French translation of the pediatric module of Duchenne Muscular Dystrophy of the PedsQL ™ 3.0 scale. The validation process is confirmatory, the scale being widely used in English. The scale will measure the quality of life of the child using two independent assessments : children and their parents.

Intervention type: OTHER
Intervention: Duchenne Muscular Dystrophy of the PedsQL ™ 3.0 scale
Description: Scaling in multidisciplinary consultations in the form of a self-administered questionnaire with the help of a third party (psychologist). The child and his / her parent complete the questionnaire independently. The result of the questionnaire will then be scored.~To validate the French translation of the pediatric module of Duchenne Muscular Dystrophy of the PedsQL ™ 3.0 scale. The validation process is confirmatory, the scale being widely used in English. The scale will measure the quality of life of the child using two independent assessments : children and their parents.

Intervention type: OTHER
Intervention: The following data of motor function
Description: In parallel, the following data are collected on the day of the consultation: assessment of motor function (MFM, use of a wheelchair, age of loss of walking); assessment of respiratory function (EFR, FVC, respiratory assistance, type of respiratory aid); evaluation of cardiac function (FE); assessment of nutritional status (weight, height, BMI, nutritional support by gastrostomy), school status; ongoing drug treatments (corticosteroids, IEC).
Study: NCT03290859

Intervention type: PROCEDURE
Intervention: Titrate propofol monotherapy infusion to effect
Description: Train anesthesia providers in a standardized protocol for titrating propofol infusion to effect.
Study: NCT03041584

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Guided placement
Description: implant placement with use of guide

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Guided placement
Description: implant placement with use of guide
Study: NCT00005092

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa
Description: IV over 2 hours on day 1

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic bone marrow transplantation
Description: Preserved stem cell or bone marrow allogeneic transplant plus psoralen treated T-cell allogeneic transplant on day 9

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: In vitro-treated peripheral blood stem cell transplantation (PBSCT)
Description: Preserved stem cell or bone marrow allogeneic transplant plus psoralen treated T-cell allogeneic transplant on day 9

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy (RT)
Description: Whole body radiotherapy on days 5-8.
Study: NCT03041584

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Guided placement
Description: implant placement with use of guide

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Guided placement
Description: implant placement with use of guide

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non-guided placement
Description: conventional implant placement

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non-guided placement
Description: conventional implant placement

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Astra Tech TX implant

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Astra Tech TX implant

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Astra Tech TX implant

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Astra Tech TX implant

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Astra Tech TX implant

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Astra Tech TX implant
Study: NCT02634892

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PRO-TECT
Description: Patient will be placed on ROHO SOFFLEX2 mattress with has been modified with gel cushions in the sacral region for heal dissipation by standard closed system cooling pad
Study: NCT04014439

Intervention type: DIAGNOSTIC_TEST
Intervention: Ratio of Neutrophil to Lymphocyte
Description: Each patient was examined for a blood sample of 6 ml of venous blood taken from the cubital vein using a vacuum tube without anticoagulants. Blood samples were centrifuged at a speed of 3500 rpm for 20 minutes. Samples are processed with abbott® devices, to obtain neutrophil and serum lymphocyte levels. Plasma samples are stored in the refrigerator -20 C. The patient's diaphragm thickness was measured on days 0, 3, 5 and then the measurement was compared. Diaphragm thickness was measured in patients using mechanical ventilation in intensive care rooms.

Intervention type: DIAGNOSTIC_TEST
Intervention: Ratio of Neutrophil to Lymphocyte
Description: Each patient was examined for a blood sample of 6 ml of venous blood taken from the cubital vein using a vacuum tube without anticoagulants. Blood samples were centrifuged at a speed of 3500 rpm for 20 minutes. Samples are processed with abbott® devices, to obtain neutrophil and serum lymphocyte levels. Plasma samples are stored in the refrigerator -20 C. The patient's diaphragm thickness was measured on days 0, 3, 5 and then the measurement was compared. Diaphragm thickness was measured in patients using mechanical ventilation in intensive care rooms.

Intervention type: DIAGNOSTIC_TEST
Intervention: Level of Prealbumin Serum
Description: Each patient was examined for a blood sample of 6 ml of venous blood taken from the cubital vein using a vacuum tube without anticoagulants. Blood samples were centrifuged at a speed of 3500 rpm for 20 minutes. Samples are processed with abbott® devices, to obtain neutrophil and serum lymphocyte levels. Plasma samples are stored in the refrigerator -20 C. The patient's diaphragm thickness was measured on days 0, 3, 5 and then the measurement was compared. Diaphragm thickness was measured in patients using mechanical ventilation in intensive care rooms.

Intervention type: DIAGNOSTIC_TEST
Intervention: Level of Prealbumin Serum
Description: Each patient was examined for a blood sample of 6 ml of venous blood taken from the cubital vein using a vacuum tube without anticoagulants. Blood samples were centrifuged at a speed of 3500 rpm for 20 minutes. Samples are processed with abbott® devices, to obtain neutrophil and serum lymphocyte levels. Plasma samples are stored in the refrigerator -20 C. The patient's diaphragm thickness was measured on days 0, 3, 5 and then the measurement was compared. Diaphragm thickness was measured in patients using mechanical ventilation in intensive care rooms.
Study: NCT01073358

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Routine hilar lymphadenectomy
Description: Hilar lymphadenectomy is performed before actual resection of the colorectal liver metastases
Study: NCT04255706

Intervention type: DEVICE
Group type: OTHER
Intervention: biometric measurement IOLMaster 700
Description: Three biometric measurements will be performed with 3 devices for all the patients included

Intervention type: DEVICE
Group type: OTHER
Intervention: biometric measurement Lenstar LS 700
Description: Three biometric measurements will be performed with 3 devices for all the patients included

Intervention type: DEVICE
Group type: OTHER
Intervention: biometric measurement Anterion Heildelberg
Description: Three biometric measurements will be performed with 3 devices for all the patients included
Study: NCT01965665

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MediHoney HCS dressing
Study: NCT00858117

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Description: Alemtuzumab administered subcutaneously 30mg per day, 3 days per week for 18 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab administered intravenously at 375mg/m2 every 2 weeks for 18 weeks
Study: NCT03094169

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVID100 IV
Description: AVID100 is administered once every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVID100 IV
Description: AVID100 is administered once every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVID100 IV
Description: AVID100 is administered once every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVID100 IV
Description: AVID100 is administered once every 3 weeks
Study: NCT00133250

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abciximab
Description: Abciximab bolus and infusion is given. Study medication includes 3 identical vials, each with 5 ml solution containing 10 mg abciximab. The bolus dose to be given should be rated at 0.125 ml/kg of patient's weight. After the bolus, a total dose of 0.045 ml/kg study substance (up to a maximal quantity of 3.6 ml) should be given over 12 hours.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Heparin Sodium
Description: Placebo bolus plus infusion is given. Study medication includes 3 identical vials, each with 5 ml solution containing 3000 U Heparin. The bolus dose to be given should be rated at 0.125 ml/kg of patient's weight. After the bolus, a total dose of 0.045 ml/kg study substance (up to a maximal quantity of 3.6 ml) should be given over 12 hours.
Study: NCT02798367

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT-I plus placebo
Description: Behavioral techniques of Sleep Hygiene and Stimulus Control standardized in clinical protocol plus placebo (01 tablet, orally, always at night one hour before bedtime) for 21(±2) days)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT-I plus placebo
Description: Behavioral techniques of Sleep Hygiene and Stimulus Control standardized in clinical protocol plus placebo (01 tablet, orally, always at night one hour before bedtime) for 21(±2) days)

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: CBT-I plus placebo
Description: Behavioral techniques of Sleep Hygiene and Stimulus Control standardized in clinical protocol plus placebo (01 tablet, orally, always at night one hour before bedtime) for 21(±2) days)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBT-I plus Melatonin 3 mg
Description: Behavioral techniques of Sleep Hygiene and Stimulus Control standardized in clinical protocol plus Melatonin 3 mg (01 tablet, orally, always at night one hour before bedtime) for 21(±2) days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBT-I plus Melatonin 5 mg
Description: Behavioral techniques of Sleep Hygiene and Stimulus Control standardized in clinical protocol plus Melatonin 5 mg (01 tablet, orally, always at night one hour before bedtime) for 21(±2) days.
Study: NCT03636334

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computer-based decision support system
Description: At intervention sites, physicians will receive training and support on use of the DSS, which will be installed on their local IT system. Individuals eligible for DSS at Intervention sites will be randomized or assigned to different drug sequence protocols for BP-lowering therapy using their current antihypertensive medications, co-morbidities, and intolerance to medications and according to the assignment plan in the Algorithm. If the protocol is not suitable for the patient because of new co-morbidities, medication intolerance or contraindication, the DSS will recommend switching to a new protocol.
Study: NCT00933712

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LACTIC ACID(ND)
Description: Dermacyd Silver Floral (Lactic Acid) sample will be applied like a curative for 6 weeks.
Study: NCT03791593

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evolocumab
Description: Evolocumab is a human IgG2 monoclonal antibody, it will add to patient treatment during 12 months.
Study: NCT04460807

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Description: Exemestane in addition to standard therapy, in Experimental arm.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Placebo in addition to standard therapy, in Control arm.
Study: NCT04079244

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Video game
Description: Children receive a tablet with a video game at their arrival on the unit until the introduction of the anesthesia mask.~The video game used is Le Héros C'est Toi, a game specially developed for the unit. The game recreates the hospital environment and includes mini-games geared to children.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Animated cartoon
Description: Children receive a tablet with an animated cartoon at their arrival on the unit until the introduction of the anesthesia mask.~The cartoon used is L'âge de glace, an animated cartoon geared to children.
Study: NCT00813657

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Women in the intervention group were enrolled in three sessions/week of individually supervised, resistance exercise training performed over the second and third trimester of pregnancy (in total 26 weeks, \~80 training sessions). Heart rate (HR) was carefully and individually controlled (≤80% of age-predicted maximum HR value, 220-age) through a heart rate monitor during the training sessions. In brief, each session consisted of 35-40 minutes of exercise divided in a light intensity (≤60% maximal heart rate) warm-up period (\~8 minutes), followed by toning and very light resistance exercises (\~20 minutes) and a light intensity cool-down (\~8 minutes) period. Resistance exercises were performed with barbells (≤3kg per exercise) or low-to-medium resistance bands (Therabands).
Study: NCT01294956

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lubricant Eye Drop
Description: 1 drop in each eye, four times a day for 42 days

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Refresh Liquigel
Description: 1 drop in each eye, four times a day for 42 days
Study: NCT04400136

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lansoprazole oral tablets 30 mg
Description: Post operative prescription
Study: NCT04342676

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: vectibex in stage iv
Study: NCT02969915

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Incentives
Description: Treatment incentives are offered to HIV-positive participants for reaching treatment targets, including retention to medical follow-up, initiating antiretroviral therapy, and maintaining high adherence with antiretroviral therapy.